6459163781
inbox/queue/ (52 unprocessed) — landing zone for new sources
inbox/archive/{domain}/ (311 processed) — organized by domain
inbox/null-result/ (174) — reviewed, nothing extractable
One-time atomic migration. All paths preserved (wiki links use stems).
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
52 lines
3.9 KiB
Markdown
52 lines
3.9 KiB
Markdown
---
|
|
type: source
|
|
title: "The 2026 GLP-1 Patent Cliff: Generics, Global Competition, and the $100 Billion M&A Race"
|
|
author: "GeneOnline News"
|
|
url: https://www.geneonline.com/the-2026-glp-1-patent-cliff-generics-global-competition-and-the-100-billion-ma-race/
|
|
date: 2026-02-01
|
|
domain: health
|
|
secondary_domains: [internet-finance]
|
|
format: article
|
|
status: unprocessed
|
|
priority: medium
|
|
tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
|
|
---
|
|
|
|
## Content
|
|
|
|
Overview of the GLP-1 generic competition landscape as patents begin expiring internationally.
|
|
|
|
**US timeline:**
|
|
- Semaglutide patents extend to 2031-2032 (US and Europe)
|
|
- No US generics expected before 2031-2033
|
|
- Orforglipron (Eli Lilly, non-peptide small molecule) could be approved Q2 2026
|
|
|
|
**International generic competition (2026):**
|
|
- Canada: First G7 nation where certain semaglutide patents expired (January 4, 2026). Sandoz, Apotex, Teva filing immediately
|
|
- Brazil: Generic competition opening March 2026. Biomm + Biocon (India) preparing generic semaglutide
|
|
- China: 17+ generic semaglutide candidates in Phase 3 trials. Monthly therapy could fall to $40-$50
|
|
- India: Patent expirations scheduled March 2026
|
|
|
|
**Price trajectory:**
|
|
- Oral Wegovy: $149-$299/month at launch (January 2026)
|
|
- Medicare deal: $245/month
|
|
- International generics: potentially $40-$50/month in some markets
|
|
- Competition will drive prices down, but volume growth offsets price compression in near term
|
|
|
|
**Pipeline competitors:**
|
|
- Orforglipron (Lilly): non-peptide oral GLP-1, potential approval Q2 2026
|
|
- Amycretin: 22% weight loss without plateau
|
|
- Multiple next-generation compounds in development
|
|
|
|
## Agent Notes
|
|
**Why this matters:** The price trajectory is the single most important variable for the GLP-1 cost-effectiveness calculation. If prices converge toward $50-100/month globally by 2030 (driven by international generic competition, even before US generics), the "inflationary through 2035" claim needs significant revision. At $50/month, GLP-1s become unambiguously cost-effective under any payment model.
|
|
**What surprised me:** Canada's patents expired January 2026 — generic filings are already happening. The $40-$50/month projection for China/India is 95%+ below current US list price. International price arbitrage pressure will affect US pricing even before US patent expiry.
|
|
**What I expected but didn't find:** No analysis of how international generic availability affects US compounding pharmacy landscape. No modeling of the price trajectory beyond "prices will decline."
|
|
**KB connections:** The price trajectory directly affects whether the existing GLP-1 claim's "inflationary through 2035" conclusion holds. If prices decline faster than assumed, the inflection point (where volume growth no longer offsets price compression) moves earlier.
|
|
**Extraction hints:** Potential claim: "International GLP-1 generic competition beginning in 2026 will compress global prices below $100/month by 2030, fundamentally changing the cost-effectiveness calculation from inflationary to cost-saving under risk-bearing payment models."
|
|
**Context:** GeneOnline is an industry publication. The $40-$50 projection for China/India may be optimistic. US prices will remain higher due to regulatory and distribution differences. But the directional pressure is clear.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
|
WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
|
|
EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
|